(Q48482267)

English

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.

scientific article published on 14 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Maciej Krzakowski

object named as

Maciej Krzakowski

4

0 references

object named as

Rodryg Ramlau

10

0 references

Armando Santoro

object named as

Armando Santoro

9

1 reference

ORCID Public Data File 2021

author name string

Thomas Brodowicz

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Tudor E Ciuleanu

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Sung Hyun Yang

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Fábio Franke

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Branka Cucevic

7

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Jayaprakash Madhavan

8

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Astra M Liepa

11

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Carla Visseren-Grul

12

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Patrick Peterson

13

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

William J John

14

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Christoph C Zielinski

15

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

publication date

14 February 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

13

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

292-299

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Quality of life after lung cancer resection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving health-related quality of life in non-small-cell lung cancer with current treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical significance of quality of life assessments in oncology: a summary for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Challenges in QOL assessment. Overview and introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A concordance test for independence in the presence of censoring.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970339-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70339-4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/22336221

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48482267&oldid=1585679846"